{"version":3,"file":"component---src-pages-barda-press-release-jsx-1878fcb59b8d47d86737.js","mappings":"6LAMe,SAASA,IACtB,OACE,gBAAC,IAAD,KACE,gBAAC,IAAD,CAAKC,MAAM,mBACX,uBAAKC,UAAS,aACZ,uBACEA,UAAU,iCACVC,IAAKC,EAAAA,EACLC,IAAI,UAEN,sBAAIH,UAAU,iDAAd,uCAGA,sBAAIA,UAAU,gDAAd,kDAGA,qBAAGA,UAAU,uBAAb,iBACA,qBAAGA,UAAU,4BAAb,qLAKA,qBAAGA,UAAU,sCAAb,4PAMA,qBAAGA,UAAU,kBAAb,sIAEyE,IACvE,gBAAC,EAAAI,KAAD,CAAMC,KAAK,sBAAsBL,UAAU,uBAA3C,uBAHF,ibAcA,qBAAGA,UAAU,kBAAb,ufAUA,qBAAGA,UAAU,kBAAb,oWAQA,qBAAGA,UAAU,kBAAb,0OAMA,qBAAGA,UAAU,kBAAb,yeAUA,qBAAGA,UAAU,4BAAb,6BACA,qBAAGA,UAAU,kBAAb,gJAIA,qBAAGA,UAAU,4BAAb,0DAGA,qBAAGA,UAAU,kBAAb,yWAQA,qBAAGA,UAAU,kBAAb,8RAME,gBAAC,EAAAI,KAAD,CACEC,KAAK,2YACLL,UAAU,uBAFZ,UANF,0JAeE,gBAAC,EAAAI,KAAD,CACEC,KAAK,8ZACLL,UAAU,uBAFZ,WAKQ,IApBV,oSA2BA,qBAAGA,UAAU,kBAAb,kDAEE,gBAAC,EAAAI,KAAD,CACEC,KAAK,6DACLL,UAAU,uBAFZ,sDAFF,sBASE,gBAAC,EAAAI,KAAD,CACEC,KAAK,4EACLL,UAAU,uBAFZ,gCATF,MAgBE,gBAAC,EAAAI,KAAD,CACEC,KAAK,6GACLL,UAAU,uBAFZ,8BAhBF,WAuBE,gBAAC,EAAAI,KAAD,CACEC,KAAK,yCACLL,UAAU,uBAFZ,qCAOF,qBAAGA,UAAU,4BAAb,sBACA,qBAAGA,UAAU,kBAAb,kBAEE,gBAAC,EAAAI,KAAD,CAAMC,KAAK,2BAA2BL,UAAU,uBAAhD,+BAIF,qBAAGA,UAAU,4BAAb,aACA,qBAAGA,UAAU,kBAAb,kDAEE,gBAAC,EAAAI,KAAD,CAAMC,KAAK,sBAAsBL,UAAU,uBAA3C,0BAIF,qBAAGA,UAAU,kBAAb,gIAGE,gBAAC,EAAAI,KAAD,CAAMC,KAAK,2BAA2BL,UAAU,uBAAhD,mC,qBC5KV,IAAe,IAA0B","sources":["webpack:///./src/pages/barda-press-release.jsx","webpack:///./src/images/logos/background-wave.png"],"sourcesContent":["import React from \"react\";\r\nimport bgWave from \"../images/logos/background-wave.png\";\r\nimport Layout from \"../components/Layout\";\r\nimport { Link } from \"gatsby-plugin-intl\";\r\nimport SEO from \"../components/SEO\";\r\n\r\nexport default function Paper() {\r\n  return (\r\n    <Layout>\r\n      <SEO title=\"Virufy | Barda\" />\r\n      <div className={`px-6 py-8`}>\r\n        <img\r\n          className=\"-z-10 absolute w-screen left-0\"\r\n          src={bgWave}\r\n          alt=\"waves\"\r\n        />\r\n        <h1 className=\" text-xl md:text-2xl text-center md:text-left\">\r\n          INTERNAL AND EXTERNAL PRESS RELEASE\r\n        </h1>\r\n        <h1 className=\"text-xl md:text-2xl text-center md:text-left\">\r\n          THE COVID-19 DETECTION FOUNDATION (dba VIRUFY)\r\n        </h1>\r\n        <p className=\"mt-4 mb-8 text-base\">July 22, 2022</p>\r\n        <p className=\"font-bold mt-4 text-base\">\r\n          THE COVID-19 DETECTION FOUNDATION (dba VIRUFY) AND BARDA ANNOUNCE\r\n          CONTRACT TO RESEARCH & DEVELOP COVID-19 SCREENING THROUGH ARTIFICIAL\r\n          INTELLIGENCE / MACHINE LEARNING TECHNOLOGY\r\n        </p>\r\n        <p className=\"text-base font-bold mt-4 text-base\">\r\n          THE COVID-19 DETECTION FOUNDATION (dba VIRUFY) COVID-19 SCREENING\r\n          THROUGH ARTIFICIAL INTELLIGENCE / MACHINE LEARNING TECHNOLOGY IS THE\r\n          NEWEST MEMBER OF BARDA’S DIVISION OF RESEARCH, INNOVATION, AND\r\n          VENTURES (DRIVe) MEDICAL COUNTERMEASURES PORTFOLIO\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          SILICON VALLEY, CA. (July 22, 2022) – The COVID-19 Detection\r\n          Foundation (dba Virufy) a 501(c)(3) non-profit research organization ({\" \"}\r\n          <Link href=\"https://virufy.org/\" className=\"text-base text-blue\">\r\n            https://virufy.org/\r\n          </Link>\r\n          ) developing a smartphone app for rapid COVID-19 screening through\r\n          artificial intelligence (AI) / machine learning (ML) technology, today\r\n          announced that it has been awarded a contract from the Biomedical\r\n          Advanced Research and Development Authority (BARDA), part of the\r\n          Office of the Assistant Secretary for Preparedness and Response\r\n          (ASPR), within the U.S. Department of Health and Human Services (HHS),\r\n          a U.S. government agency.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          This project aims to research and develop COVID-19 screening through\r\n          AI / ML Technology. Virufy’s patented and patent-pending solution\r\n          gathers a patient’s cough / speech data and then, using AI / ML\r\n          algorithm, rapidly analyzes that data against known COVID-19\r\n          Polymerase chain reaction (PCR)-positive, and Covid-19 PCR-negative\r\n          cough datasets to indicate potential active COVID-19 infection. PCR\r\n          testing is universally acknowledged as the gold-standard in molecular\r\n          diagnostics and COVID-19 testing.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          This Virufy project aims to empower individuals, clinicians,\r\n          employers, and governments with early, actionable COVID-19\r\n          information, to provide cost-effective, faster results for capturing\r\n          and predicting health events anda reduction in overburdening scarce\r\n          healthcare resources so that timely responses and medical\r\n          interventions can be better deployed.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          While Virufy has obtained a contract with BARDA, the limited funds are\r\n          contractually restricted to contract deliverables and data collection,\r\n          and we remain a 501(c)(3) entity principally staffed by volunteers and\r\n          pro bono vendors.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          “We are profoundly appreciative of the hundreds of volunteers and\r\n          dozens of pro-bono firms that have selflessly donated their time,\r\n          creativity, expertise, and compassion in support of our Mission of\r\n          public good, and for BARDA’s / DRIVe’s generous support to fund the\r\n          advancement of Virufy’s Covid-19 screening through AI / ML technology”\r\n          said Virufy CEO, Amil Khanzada. This project has been funded in part\r\n          with Federal funds from HHS/ASPR and BARDA, under Contract No.\r\n          75A50122C00034.\r\n        </p>\r\n        <p className=\"text-base font-bold mt-8\">Additional Information - </p>\r\n        <p className=\"text-base mt-4\">\r\n          This award is one component of BARDA’s rapidly expanding DRIVe Medical\r\n          countermeasures portfolio, visit https://drive.hhs.gov to learn more.\r\n        </p>\r\n        <p className=\"text-base font-bold mt-8\">\r\n          About the COVID-19 Detection Foundation (dba Virufy) -\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          The COVID-19 Detection Foundation (dba Virufy) is a 501(c)(3)\r\n          nonprofit research organization developing artificial intelligence\r\n          (AI) / machine learning (ML) technology offering superior, actionable\r\n          COVID-19 information, to provide faster results for capturing and\r\n          predicting health events so that timely responses and medical\r\n          interventions can be deployed.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          About HHS, ASPR, and BARDA: The U.S. Department of Health and Human\r\n          Services works to enhance and protect the health and well-being of all\r\n          Americans, providing for effective health and human services and\r\n          fostering advances in medicine, public health, and social services.\r\n          Within HHS,\r\n          <Link\r\n            href=\"https://gcc02.safelinks.protection.outlook.com/?url=http%3A%2F%2Faspr.hhs.gov%2F&data=05%7C01%7CElizabeth.Kane%40hhs.gov%7Cb08b8231af95400491fa08da638b2025%7Cd58addea50534a808499ba4d944910df%7C0%7C0%7C637931746429939141%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=3%2BMUqUprhLMbSMhD94xCfgrL7BKrhWJWnokEcI23Gmw%3D&reserved=0\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            &nbsp;ASPR&nbsp;\r\n          </Link>\r\n          leads the nation’s medical and public health preparedness for,\r\n          response to, and recovery from disasters and public health\r\n          emergencies. As part of ASPR,\r\n          <Link\r\n            href=\"https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.medicalcountermeasures.gov%2F&data=05%7C01%7CElizabeth.Kane%40hhs.gov%7Cb08b8231af95400491fa08da638b2025%7Cd58addea50534a808499ba4d944910df%7C0%7C0%7C637931746429939141%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=Lr3bXCSJexmefnIfO3OTh%2FDfwaqubVBfDBpEf7lZyXU%3D&reserved=0\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            &nbsp;BARDA&nbsp;\r\n          </Link>{\" \"}\r\n          provides a comprehensive, integrated, portfolio approach to the\r\n          advanced research and development, innovation, acquisition, and\r\n          manufacturing of medical countermeasures – vaccines, drugs,\r\n          therapeutics, diagnostic tools, and non-pharmaceutical products for\r\n          public health emergency threats.\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          To date, BARDA-supported products have achieved\r\n          <Link\r\n            href=\"https://www.medicalcountermeasures.gov/barda/fdaapprovals/\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            &nbsp;over 60 FDA approvals, licensures or clearances.&nbsp;\r\n          </Link>\r\n          To learn more about\r\n          <Link\r\n            href=\"https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            &nbsp;BARDA's COVID-19 Portfolio&nbsp;\r\n          </Link>\r\n          and\r\n          <Link\r\n            href=\"https://www.medicalcountermeasures.gov/app/barda/COVIDTimeline.aspx#event-bardaacovid-19aresponseatimeline\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            &nbsp;BARDA’s COVID-19 Response\r\n          </Link>\r\n          , visit&nbsp;\r\n          <Link\r\n            href=\"http://www.medicalcountermeasures.gov/\"\r\n            className=\"text-base text-blue\"\r\n          >\r\n            www.medicalcountermeasures.gov/.\r\n          </Link>\r\n        </p>\r\n        <p className=\"text-base font-bold mt-8\">Published Works - </p>\r\n        <p className=\"text-base mt-4\">\r\n          May be found at\r\n          <Link href=\"https://virufy.org/paper\" className=\"text-base text-blue\">\r\n            &nbsp;https://virufy.org/paper&nbsp;\r\n          </Link>\r\n        </p>\r\n        <p className=\"text-base font-bold mt-8\">Contact -</p>\r\n        <p className=\"text-base mt-4\">\r\n          For more information about Virufy, please visit\r\n          <Link href=\"https://virufy.org/\" className=\"text-base text-blue\">\r\n            &nbsp;https://virufy.org/&nbsp;\r\n          </Link>\r\n        </p>\r\n        <p className=\"text-base mt-4\">\r\n          For information pertaining to this press release, please contact\r\n          Patrick O’Neill, Managing Partner, Sherlock Communications -\r\n          <Link href=\"virufy@sherlockcomms.com\" className=\"text-base text-blue\">\r\n            &nbsp;virufy@sherlockcomms.com&nbsp;\r\n          </Link>\r\n        </p>\r\n      </div>\r\n    </Layout>\r\n  );\r\n}\r\n","export default __webpack_public_path__ + \"static/background-wave-4b46ad589f1ae976934a2f1b063fc0b9.png\";"],"names":["Paper","title","className","src","bgWave","alt","Link","href"],"sourceRoot":""}